Deciphering mRNA Signatures: A Comprehensive Review of Biomarker Discovery for Targeted Pancreatic Cancer Therapies
Keywords:
Pancreatic cancer, mRNA, biomarkers, targeted therapyAbstract
Pancreatic cancer, particularly pancreatic adenocarcinoma (PDAC), remains a formidable adversary in the world of medicine. It's a disease marked by its aggressive nature, often diagnosed too late, and stubbornly resistant to our current treatments. This urgent reality compels us to find new, highly specific tools – what we call biomarkers – that can revolutionize how we detect it early, understand its progression, and most importantly, guide us toward therapies that truly hit their mark. Think of messenger RNA (mRNA) molecules as the dynamic storytellers within our cells, constantly revealing the active biological processes of cancer. This comprehensive review embarks on a journey through the evolving landscape of how we identify these mRNA-based biomarkers in pancreatic cancer. We'll uncover their immense potential to usher in an era of truly personalized medicine. We'll dive into the meticulous methods scientists use, from advanced sequencing technologies to sophisticated computational detective work. Along the way, we'll shine a light on promising mRNA candidates that are emerging from rigorous research, exploring their biological significance and how they could profoundly influence the design of tailored treatments for each patient. The exciting synergy between cutting-edge molecular tools and advanced computing is steadily deepening our grasp of pancreatic cancer's intricate biological secrets, paving the way for more effective, gentler, and truly personalized treatment paths..
References
1. Siegel, R.L.; Miller, K.D.; Wagle, N.S.; Jemal, A. Cancer statistics, 2023. CA Cancer J. Clin. 2023, 73, 17–48. [CrossRef]
2. Mizrahi, J.D.; Surana, R.; Valle, J.W.; Shroff, R.T. Pancreatic cancer. Lancet 2020, 395, 2008–2020. [CrossRef]
3. Halbrook, C.J.; Lyssiotis, C.A.; di Magliano, M.P.; Maitra, A. Pancreatic cancer: Advances and challenges. Cell 2023, 186, 1729–1754. [CrossRef] [PubMed]
4. Huang, J.; Lok, V.; Ngai, C.H.; Zhang, L.; Yuan, J.; Lao, X.Q.; Ng, K.; Chong, C.; Zheng, Z.J.; Wong, M.C. Worldwide burden of, risk factors for, and trends in pancreatic cancer. Gastroenterology 2021, 160, 744–754. [CrossRef] [PubMed]
5. Huang, X.; Zhang, G.; Tang, T.Y.; Gao, X.; Liang, T.B. Personalized pancreatic cancer therapy: From the perspective of mRNA vaccine. Mil. Med. Res. 2022, 9, 53. [CrossRef] [PubMed]
6. Liu, B.; Yang, H.; Taher, L.; Denz, A.; Grützmann, R.; Pilarsky, C.; Weber, G.F. Identification of prognostic biomarkers by combined mRNA and miRNA expression microarray analysis in pancreatic cancer. Transl. Oncol. 2018, 11, 700–714. [CrossRef]
7. Stefanovic, S.; Wirtz, R.; Deutsch, T.M.; Hartkopf, A.; Sinn, P.; Varga, Z.; Sobottka, B.; Sotiris, L.; Taran, F.A.; Domschke, C.; et al. Tumor biomarker conversion between primary and metastatic breast cancer: mRNA assessment and its concordance with immunohistochemistry. Oncotarget 2017, 8, 51416. [CrossRef]
8. He, J.; Wu, F.; Han, Z.; Hu, M.; Lin, W.; Li, Y.; Cao, M. Biomarkers (mRNAs and Non-Coding RNAs) for the diagnosis and prognosis of colorectal cancer–from the body fluid to tissue level. Front. Oncol. 2021, 11, 632834. [CrossRef]
9. Xing, L.; Lv, L.; Ren, J.; Yu, H.; Zhao, X.; Kong, X.; Xiang, H.; Tao, X.; Dong, D. Advances in targeted therapy for pancreatic cancer. Biomed. Pharmacother. 2023, 168, 115717. [CrossRef]
10. Tan, A.C.; Tan, D.S. Targeted therapies for lung cancer patients with oncogenic driver molecular alterations. J. Clin. Oncol. 2022, 40, 611–625. [CrossRef]
11. Zhu, K.; Wu, Y.; He, P.; Fan, Y.; Zhong, X.; Zheng, H.; Luo, T. PI3K/AKT/mTOR-targeted therapy for breast cancer. Cells 2022, 11, 2508. [CrossRef] [PubMed]
12. Edgar, R.; Domrachev, M.; Lash, A.E. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002, 30, 207–210. [CrossRef] [PubMed]
13. Agapito, G.; Milano, M.; Cannataro, M. A statistical network pre-processing method to improve relevance and significance of gene lists in microarray gene expression studies. BMC Bioinform. 2022, 23, 393. [CrossRef] [PubMed]
14. Ritchie, M.E.; Phipson, B.; Wu, D.; Hu, Y.; Law, C.W.; Shi, W.; Smyth, G.K. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015, 43, e47.
15. Baus-Loncar, M.; Giraud, A.S. Trefoil factors: Multiple regulatory pathways for trefoil factor (TFF) genes. Cell. Mol. Life Sci. CMLS 2005, 62, 2921–2931.
16. Fu, T.; Liu, J.X.; Xie, J.; Gao, Z.; Yang, Z. LAMC2 as a prognostic biomarker in human cancer: A systematic review and meta-analysis. BMJ Open 2022, 12, e063682. [CrossRef]
17. O’Neill, R.S.; Stoita, A. Biomarkers in the diagnosis of pancreatic cancer: Are we closer to finding the golden ticket? World J. Gastroenterol. 2021, 27, 4045.
18. Shen, G.Q.; Aleassa, E.M.; Walsh, R.M.; Morris-Stiff, G. Next-generation sequencing in pancreatic cancer. Pancreas 2019, 48, 739–748.
19. Cicenas, J.; Kvederaviciute, K.; Meskinyte, I.; Meskinyte-Kausiliene, E.; Skeberdyte, A.; Cicenas, J., Jr. KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 mutations in pancreatic cancer. Cancers 2017, 9, 42. [CrossRef]
20. Jahan, R.; Shah, A.; Kisling, S.G.; Macha, M.A.; Thayer, S.; Batra, S.K.; Kaur, S. Odyssey of trefoil factors in cancer: Diagnostic and therapeutic implications. Biochim. Biophys. Acta (BBA) Rev. Cancer 2020, 1873, 188362.
21. Erice, O.; Narayanan, S.; Feliu, I.; Entrialgo-Cadierno, R.; Malinova, A.; Vicentini, C.; Guruceaga, E.; Delfino, P.; Trajkovic-Arsic, M.; Moreno, H.; et al. LAMC2 regulates key transcriptional and targetable effectors to support pancreatic cancer growth. Clin. Cancer Res. 2023, 29, 1137–1154. [CrossRef] [PubMed]